Approaches to overcome the challenge of sample stability for flow cytometry analysis in clinical trials

References

• 1. van der Strate B, Longdin B, Geerlings M et al. Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum. Bioanalysis 9(16), 1253–1264 (2017).
  Google Scholar
• 2. Brown L, Green CL, Jones N et al. Recommendations for the evaluation of specimen stability for flow cytometric testing during drug development. J. Immunol. Methods 418, 1–8 (2015).
  Medline CASGoogle Scholar
• 3. Yu J, Jasti S, Mason D et al. Extending flow cytometry sample stability by freezing lysed whole blood for clinical monitoring of regulatory T cells. Bioanalysis 12, 655–663 (2020).
  CASGoogle Scholar
• 4. Diks AM, Bonroy C, Teodosio C et al. Impact of blood storage and sample handling on quality of high dimensional flow cytometric data in multicenter clinical research. J. Immunol. Methods 475, 1–13 (2019).
  Google Scholar
• 5. Spitz S, Zhang Y, Fisher S et al. 2020 White Paper on recent issues in bioanalysis: BAV guidance, CLSI H62, biotherapeutics stability, parallelism testing, CyTOF and regulatory feedback (part 2A – recommendations on biotherapeutics stability, PK LBA regulated bioanalysis, biomarkers assays, cytometry validation & innovation part 2B– regulatory agencies' inputs on bioanalysis, biomarkers, immunogenicity, gene & cell therapy and vaccine). Bioanalysis 13(5), 295–361 (2021).
  CASGoogle Scholar